INSM vs SION
INSM: A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in respiratory, immunology, and neurological rare diseases. SION: A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis.
Side-by-side fundamentals
| Metric | INSM | SION | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $106.64 | $45.03 | |
| Market cap as of 2026-07-23 | $23.4B | $2.1B | |
| PEG as of 2026-07-23 | n/a | -0.90 | |
| Net margin as of 2026-07-23 | -144.4% | n/a | |
| Gross margin as of 2026-07-23 | +81.8% | n/a | |
| Operating margin as of 2026-07-23 | -140.6% | n/a | |
| ROE as of 2026-07-23 | -130.1% | -27.3% | SION higher |
| ROA as of 2026-07-23 | -51.6% | -25.9% | SION higher |
| Debt / equity as of 2026-07-23 | 1.03 | 0.00 | SION lower |
| Revenue growth (YoY) as of 2026-07-23 | +115.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +35.2% | n/a | |
| Beta as of 2026-07-23 | 0.80 | 1.40 | |
| 1-year return as of 2026-07-22 close | +5.7% | +170.7% | SION higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.